TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16798861

Group type: EXPERIMENTAL
Intervention: CO2 laser irradiation plus non-fluoride dentifrice
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: CO2 laser irradiation plus fluoride dentifrice
Number of subjects: 17

Group type: COMPARATOR
Intervention: non-fluoride dentifrice
Number of subjects: 17
Study: 12428638

Group type: EXPERIMENTAL
Intervention: Sevoflurane 8%
Number of subjects: 61

Group type: COMPARATOR
Intervention: Propofol target‐controlled infusion at 6 microg.ml(‐1)
Number of subjects: 61
Study: 9670176

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional medical management
Number of subjects: 0
Study: 7927547

Group type: EXPERIMENTAL
Intervention: C. trachomatis antigen detection
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: T. gondii (IgM) antibodies detection
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: M. hominis (IgG) antibodies detection
Number of subjects: 365

Group type: COMPARATOR
Intervention: Control group (100 women with normal infants)
Number of subjects: 365
Study: 2690235

Group type: EXPERIMENTAL
Intervention: Bromhexine 30 mg b.i.d. p.o.
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study: 1096695

Group type: EXPERIMENTAL
Intervention: Inductive method (deriving rules from pulmonary function data and correct diagnoses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deductive method (using a computer-assisted instructional program)
Number of subjects: 0
Study: 31855922

Group type: EXPERIMENTAL
Intervention: Aspiration without prior lavage (Group I)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Aspiration after lavage with 500 mL physiological saline (Group II)
Number of subjects: 286
Study: 31293193

Group type: EXPERIMENTAL
Intervention: Mobile-bearing (MB) Oxford UKA
Number of subjects: 62

Group type: COMPARATOR
Intervention: Fixed-bearing (FB) Sigma UKA
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups (MB and FB)
Number of subjects: 62
Study: 28677879

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 530

Group type: COMPARATOR
Intervention: Appendicectomy
Number of subjects: 530
Study: 23911057

Group type: EXPERIMENTAL
Intervention: Medication Recommendation Tracking Form (MRTF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previous CGI-BP depression score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previous CGI-BP overall severity score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previous Montgomery Asberg Depression Rating Scale (MADRS) score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previous Young Mania Rating Scale (YMRS) score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fewer NCAs
Number of subjects: 0
Study: 21293307

Group type: EXPERIMENTAL
Intervention: Low graduated compression stockings (12-15 mm Hg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Medium graduated compression stockings (18-21 mm Hg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (0 mm Hg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High graduated compression stockings (23-32 mm Hg)
Number of subjects: 12
Study: 19656211

Group type: EXPERIMENTAL
Intervention: Zofenopril
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1400
Study: 17429085

Group type: EXPERIMENTAL
Intervention: DPT-Hib-IPV (Group A)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: DPT-Hib-IPV (Group C)
Number of subjects: 166

Group type: COMPARATOR
Intervention: DPT-Hib (Group B)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: DPT-Hib-IPV (Group A, C)
Number of subjects: 166
Study: 15587100

Group type: EXPERIMENTAL
Intervention: Nonrinsing conditioner (NRC) with Prime & Bond NT/PMRC sealants
Number of subjects: 141

Group type: COMPARATOR
Intervention: Phosphoric acid-conditioned Prime & Bond NT/PMRC sealants
Number of subjects: 141

Group type: COMPARATOR
Intervention: Phosphoric acid-conditioned Delton sealants
Number of subjects: 141
Study: 11463764

Group type: EXPERIMENTAL
Intervention: Sodium-restricted diet
Number of subjects: 38

Group type: COMPARATOR
Intervention: Ordinary sodium diet
Number of subjects: 38
Study: 9722222

Group type: EXPERIMENTAL
Intervention: Short-term immunotherapy (STI) with seven preseasonal injections of tree-pollen allergens (ALK7 Frühblühermischung)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Short-term immunotherapy (STI)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 8276370

Group type: EXPERIMENTAL
Intervention: Amiloride (20 mg initial dose, increased to 60 mg/day if no response)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Potassium canrenoate (150 mg initial dose, increased to 500 mg/day if no response)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Potassium canrenoate (for nonresponders to amiloride)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Amiloride (for nonresponders to potassium canrenoate)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison of responders and nonresponders to potassium canrenoate
Number of subjects: 40
Study: 2346202

Group type: COMPARATOR
Intervention: Tono-Pen
Number of subjects: 130

Group type: COMPARATOR
Intervention: Pulsair
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometer
Number of subjects: 130
Study: 1203840

Group type: EXPERIMENTAL
Intervention: Continuous 120-hours infusion of 5-fluorouracil
Number of subjects: 70

Group type: COMPARATOR
Intervention: Intravenous bolus injection of 5-fluorouracil daily for 5 days
Number of subjects: 70
Study: 31823527

Group type: EXPERIMENTAL
Intervention: 1 mg rasagiline tablet (single dose)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1.25 mg rasagiline transdermal patch (48-hour patch-on period)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2.5 mg rasagiline transdermal patch (48-hour patch-on period)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1 mg rasagiline tablet (repeated doses for 7 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1.25 mg rasagiline transdermal patch (repeated doses every 72 hours for 5 time periods)
Number of subjects: 30
Study: 30715568

Group type: EXPERIMENTAL
Intervention: Tile AO classification
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Young and Burgess classification
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: FFP classification
Number of subjects: 154
Study: 28436727

Group type: EXPERIMENTAL
Intervention: Polypill-based treatment (aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg and either atenolol 50 mg or hydrochlorothiazide 12.5 mg)
Number of subjects: 2004

Group type: EXPERIMENTAL
Intervention: Polypill-based treatment
Number of subjects: 2004

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2004
Study: 25758280

Group type: EXPERIMENTAL
Intervention: NOV FFR technique
Number of subjects: 56

Group type: COMPARATOR
Intervention: CON FFR technique
Number of subjects: 56
Study: 23526462

Group type: EXPERIMENTAL
Intervention: Intralipid (IL) infusion
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 46
Study: 21470450

Group type: EXPERIMENTAL
Intervention: Intensive hand hygiene campaign (washing hands twice each day and health messages through entertainment activities)
Number of subjects: 60
Study: 19309189

Group type: EXPERIMENTAL
Intervention: Multicomponent, classroom-based intervention (Chicago School Readiness Project model)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 35
Study: 16857049

Group type: EXPERIMENTAL
Intervention: Chronic Disease Self‐Management Program (CDSMP) consisting of six weekly sessions led by a CHF nurse specialist and a CHF patient.
Number of subjects: 318

Group type: COMPARATOR
Intervention: Care as usual (Control group).
Number of subjects: 318
Study: 16627035

Group type: EXPERIMENTAL
Intervention: Bipolar cautery
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Hulka clip
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control (Barrier contraception or abstinence)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Bipolar cautery and Hulka clip
Number of subjects: 118
Study: 14713182

Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 10366121

Group type: EXPERIMENTAL
Intervention: Self-care education (group E)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Attention control (group AC)
Number of subjects: 211
Study: 7572943

Group type: EXPERIMENTAL
Intervention: Galvin insulin sensitivity measure (calculated from FSIGT)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Minimal model analysis (MINMOD SI(22))
Number of subjects: 55
Study: 2178497

Group type: EXPERIMENTAL
Intervention: 200 micrograms/day triamcinolone acetonide aerosol
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 154301

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30799495

Group type: EXPERIMENTAL
Intervention: e‐Motivate 1.0
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: e‐Motivate 2.0
Number of subjects: 38
Study: 30615666

Group type: EXPERIMENTAL
Intervention: Combined training
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 69
Study: 27802114

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (smokers with a quit goal)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (smokers)
Number of subjects: 200
Study: 25770824

Group type: EXPERIMENTAL
Intervention: 200 ppm toluene exposure
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (not exposed to toluene)
Number of subjects: 33
Study: 23538154

Group type: EXPERIMENTAL
Intervention: Transradial catheterisation (TR, n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Transfemoral catheterisation (TF, n=20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (TR and TF)
Number of subjects: 40
Study: 21565557

Group type: EXPERIMENTAL
Intervention: Microcarrier-bound human retinal pigment epithelial (RPE) cells transplantation
Number of subjects: 71

Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 71
Study: 18795378

Group type: EXPERIMENTAL
Intervention: 800 IU/day Vitamin D3
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 2000 IU/day Vitamin D3
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 5000 IU/day Vitamin D3
Number of subjects: 45
Study: 17088399

Group type: EXPERIMENTAL
Intervention: Central venous catheter serum gentamicin concentration
Number of subjects: 45

Group type: COMPARATOR
Intervention: Peripheral serum gentamicin concentration
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Central venous catheter sample result
Number of subjects: 45
Study: 15122592

Group type: EXPERIMENTAL
Intervention: High serum levels of IGF-I (highest quartile)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: High serum levels of IGFBP-3
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Adjustment for IGFBP-3 or IGF-I
Number of subjects: 69
Study: 11157836

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (800 microg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Surgical curettage (control)
Number of subjects: 80
Study: 9212354

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 33
Study: 8361248

Group type: EXPERIMENTAL
Intervention: VA‐ADHC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Customary care
Number of subjects: 0
Study: 3017039

Group type: EXPERIMENTAL
Intervention: Clonidine 4 micrograms kg‐1 before surgery, 2 micrograms kg‐1 after cardiopulmonary by‐pass and 1 microgram kg‐1 when the skin was sutured.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no clonidine)
Number of subjects: 40
Study: 31892526

Group type: EXPERIMENTAL
Intervention: Higher levels of total plasma apoC3
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Total apoA1 levels
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Plasma concentrations of apoA1 in HDL and its apolipoprotein‐defined subspecies
Number of subjects: 995
Study: 31068221

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Endotracheal intubation (ETI)
Number of subjects: 6000
Study: 29025835

Group type: EXPERIMENTAL
Intervention: CML-enhanced maternal milk formulation
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Standard maternal milk formulation
Number of subjects: 1500

Group type: COMPARATOR
Intervention: No maternal milk intervention with standard pregnancy advice
Number of subjects: 1500
Study: 26421525

Group type: EXPERIMENTAL
Intervention: Low-intensity laser treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 23160656

Group type: EXPERIMENTAL
Intervention: 12 °C (mild-cold)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 21 °C (control)
Number of subjects: 16
Study: 21481024

Group type: EXPERIMENTAL
Intervention: Oral desensitization
Number of subjects: 60

Group type: COMPARATOR
Intervention: Milk-free diet (Control)
Number of subjects: 60
Study: 19784514

Group type: EXPERIMENTAL
Intervention: Neurostimulation (NE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ultrasound (US)
Number of subjects: 40
Study: 17000686

Group type: EXPERIMENTAL
Intervention: Abagovomab 2.0 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Abagovomab 0.2 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Abagovomab (route i.m. or s.c.)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 42
Study: 15366639

Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 3454

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3454
Study: 12566890

Group type: EXPERIMENTAL
Intervention: Latanoprost additive therapy
Number of subjects: 35
Study: 9701293

Group type: EXPERIMENTAL
Intervention: 1 mg dihydroergotamine (DHE)
Number of subjects: 171

Group type: COMPARATOR
Intervention: 1.5 mg/kg meperidine (MEP)
Number of subjects: 171
Study: 7981460

Group type: EXPERIMENTAL
Intervention: Droloxifene 20 mg daily
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Droloxifene 40 mg daily
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Droloxifene 100 mg daily
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Droloxifene (pooled 40 + 100 mg)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Droloxifene 100 mg
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Droloxifene 40 mg
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Droloxifene (all dosages)
Number of subjects: 292
Study: 2657320

Group type: EXPERIMENTAL
Intervention: Pulsatile Insulin (PI) - 75% of 32 mU/kg/h delivered as 40-second pulses every 13 minutes
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Continuous Insulin (CI) - 32 mU/kg/h continuous infusion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Continuous Insulin (CI) - second 12 CI infusions
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pulsatile Insulin (PI) followed by Continuous Insulin (CI)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Continuous Insulin (CI) followed by Continuous Insulin (CI)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pulsatile Insulin (PI) - first infusion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Continuous Insulin (CI) - first infusion
Number of subjects: 6
Study: 31463482

Group type: EXPERIMENTAL
Intervention: Patency group (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonpatency group (n = 25)
Number of subjects: 50
Study: 29030478

Group type: EXPERIMENTAL
Intervention: Early statin therapy within 24 hours after admission
Number of subjects: 257

Group type: COMPARATOR
Intervention: Delayed statin therapy on the seventh day after admission
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Early statin therapy
Number of subjects: 257

Group type: COMPARATOR
Intervention: Delayed statin therapy
Number of subjects: 257
Study: 25961617

Group type: EXPERIMENTAL
Intervention: Amine fluoride mouth rinse
Number of subjects: 30

Group type: COMPARATOR
Intervention: Chlorhexidine mouth rinse
Number of subjects: 30
Study: 24260889

Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IORT) with 15 Gy, preoperative chemotherapy with paclitaxel/carboplatin, and radiosensitization with cisplatin
Number of subjects: 147

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 147
Study: 22056385

Group type: EXPERIMENTAL
Intervention: Oral administration of diazoxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intracerebroventricular (i.c.v.) administration of glibenclamide
Number of subjects: 0
Study: 19291011

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha-2a + ribavirin 800 mg/day (Group A)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha-2a + ribavirin 400 mg/day (Group B)
Number of subjects: 17
Study: 16458136

Group type: EXPERIMENTAL
Intervention: Tibolone for six months
Number of subjects: 26

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 26
Study: 15513697

Group type: EXPERIMENTAL
Intervention: High sodium diet (309 +/- 88 mmol/day)
Number of subjects: 48
Study: 10955697

Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide (TAA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cetirizine (antihistamine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 0
Study: 8846524

Group type: EXPERIMENTAL
Intervention: Individualized heparin dosing protocol with a loading dose of 50 u/kg and continuous infusion of 15 u/kg/h, adjusted with a sliding scale to target WBAPPT in the range of 150-190 seconds.
Number of subjects: 31
Study: 1519829

Group type: EXPERIMENTAL
Intervention: Allergen inhalation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control solutions
Number of subjects: 16
Study: 6568354

Group type: EXPERIMENTAL
Intervention: Group 1 - monthly measurements and reinforcement of behavioral, diet, and exercise components
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Group 2 - monthly measurements
Number of subjects: 15

Group type: COMPARATOR
Intervention: Group 3 - annual measurements
Number of subjects: 15
Study: 31648401

Group type: EXPERIMENTAL
Intervention: Autoimplantation technique every 2 weeks for a maximum of four treatments
Number of subjects: 80

Group type: COMPARATOR
Intervention: MMR intralesional injection at a dose of 0.5 ml every 2 weeks for a maximum of four treatments
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Autoimplantation technique
Number of subjects: 80

Group type: COMPARATOR
Intervention: MMR intralesional injection
Number of subjects: 80
Study: 28816894

Group type: EXPERIMENTAL
Intervention: Operative treatment (ORIF)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 301
Study: 24885514

Group type: EXPERIMENTAL
Intervention: Personal HIV blog
Number of subjects: 261

Group type: COMPARATOR
Intervention: Institutional HIV website
Number of subjects: 261
Study: 23742058

Group type: EXPERIMENTAL
Intervention: Dilute wood smoke exposure (mean particle concentration of 314±38 μg/m3)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 14
Study: 21284478

Group type: EXPERIMENTAL
Intervention: Insulin glargine at 60% of TDI
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Insulin glargine at 80% of TDI
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Insulin glargine based on TDI and body weight
Number of subjects: 223
Study: 19368584

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 16491577

Group type: EXPERIMENTAL
Intervention: 15 kPa PIO2
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 10 kPa PIO2
Number of subjects: 13

Group type: COMPARATOR
Intervention: 21 kPa PIO2 (control)
Number of subjects: 13
Study: 15514265

Group type: EXPERIMENTAL
Intervention: Pinitol supplementation (2000 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (non-nutritive beverage)
Number of subjects: 15
Study: 11075743

Group type: EXPERIMENTAL
Intervention: Cellulose Acetate (CA)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Polysulfone (PS)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Cellulose Acetate (CA) in ICU
Number of subjects: 66

Group type: COMPARATOR
Intervention: Polysulfone (PS) in ICU
Number of subjects: 66
Study: 9228438

Group type: EXPERIMENTAL
Intervention: Statin drugs
Number of subjects: 29000
Study: 1428560

Group type: EXPERIMENTAL
Intervention: XPERT NCT (Reichert)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 300
Study: 3880686

Group type: EXPERIMENTAL
Intervention: Triamterene-hydrochlorothiazide
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Amiloride-hydrochlorothiazide
Number of subjects: 84
Study: 3305461

Group type: COMPARATOR
Intervention: Ceftazidime sodium (1 or 2 g intramuscular injections, three times daily)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ceftazidime arginine (1 or 2 g intramuscular injections, three times daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ceftazidime sodium (1 g injections)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ceftazidime arginine (1 g injections)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ceftazidime sodium (2 g injections)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ceftazidime arginine (2 g injections)
Number of subjects: 100
Study: 31914105

Group type: EXPERIMENTAL
Intervention: Peer specialist services (community-based, structured curriculum for recovery, up to 40 weekly sessions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protocol adherent peer specialist services
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (case management services)
Number of subjects: 0
Study: 30574603

Group type: EXPERIMENTAL
Intervention: Flowable resin composite
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Resin-based sealant
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control
Number of subjects: 35